Program
Tin Fluorides
Also written as “0.454% Stannous Fluoride Dentifrice”, “Stannous fluoride toothpaste” and “Stannous Fluoride”.
Its studies are mostly in Gingivitis · Dentin Sensitivity · Dental Plaque · Diabetes Mellitus, Type 2 · Halitosis, led by 5 companies.
Drug pageTin Fluorides: every studyMany companies study it; this page follows only the 47 they lead. All 44 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Colgate Palmoliveits history only | 182 open or running | phase 4since Feb 6, 2015 | Sep 26, 2008 | Sep 2027phase 4 · NCT07807397 |
| Procter and Gambleits history only | 142 open or running | phase 4since Aug 28, 2025 | Feb 28, 2012 | none ahead |
| GlaxoSmithKline | 80 open or running | phase 3since May 3, 2012 | May 3, 2012 | none ahead |
| HALEONits history only | 40 open or running | no phasesince Nov 16, 2023 | Nov 16, 2023 | none ahead |
| Church & Dwightits history only | 30 open or running | no phasesince Feb 12, 2026 | Feb 12, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 3, 2012First studies: 2 phase 3 studies in Dentin SensitivityFirst studyNCT01592864, NCT01592851
- Apr 5, 2013Phase 3 study in Dentin SensitivityNCT01827670 · 119 enrolled · United States
- Nov 2, 2015No phase study in GingivitisNCT02750943 · 253 enrolled · United States
- Mar 28, 2016Phase 3 study in Dentin SensitivityNCT02832375 · 242 enrolled · United States
- Apr 25, 2016No phase study in Dentin SensitivityNCT02752958 · 75 enrolled · United Kingdom
- Mar 2, 2017Phase 3 study in Dentin SensitivityNCT03072719 · 120 enrolled · Ireland
- Oct 10, 2019Phase 3 study in GingivitisNCT04123665 · 98 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04123665Gingivitis · United States | 3 | Completed | Dec 11, 2013 | 98 |
| NCT03072719Dentin Sensitivity · Ireland | 3 | Completed | Jun 1, 2012 | 120 |
| NCT02752958Dentin Sensitivity · United Kingdom | – | Completed | Feb 1, 2017 | 75 |
| NCT02832375Dentin Sensitivity · United States | 3 | Completed | May 1, 2016 | 242 |
| NCT02750943Gingivitis · United States | – | Completed | Mar 1, 2016 | 253 |
| NCT01827670Dentin Sensitivity · United States | 3 | Completed | May 2013 | 119 |
| NCT01592864Dentin Sensitivity · United States | 3 | Completed | May 2012 | 120 |
| NCT01592851Dentin Sensitivity · United States | 3 | Completed | May 2012 | 113 |
How it is read
Names in the registry
- “0.454% Stannous Fluoride Dentifrice”, 8 entries
- “Stannous fluoride toothpaste”, 7 entries
- “Stannous Fluoride”, 6 entries
- “stannous fluoride toothpaste”, 5 entries
- “Stannous Fluoride Toothpaste (SnF)”, 5 entries
Conditions, from the studies’ own filings
- Gingivitis, 20 studies
- Dentin Sensitivity, 8 studies
- Dental Plaque, 7 studies
- Diabetes Mellitus, Type 2, 1 study
- Halitosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.